Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-101A in Relapsed/Refractory Advanced Hematologic Malignancies
NCT04504708Phase 2Terminated
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZX-101A in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL) (8 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Recommended Phase 2 Dose and Safety and Tolerability of ZX-101A up to 2 years. Started Feb 2021; status: terminated.
02
Drugs
ZX-101A
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04504708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504708.